Overview

A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)

Status:
Recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
ROSETTA STUDY: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe ulcerative colitis (UC)
Phase:
Phase 2
Details
Lead Sponsor:
AnaptysBio, Inc.